Literature DB >> 10882215

Sjögren's syndrome: autoimmune epithelitis.

M N Manoussakis1, H M Moutsopoulos.   

Abstract

Sjögren's syndrome (SS) is a chronic autoimmune disorder of the exocrine glands of unknown aetiology, which is typically associated with focal lymphocytic infiltrates of glandular tissues and autoantibody responses against the Ro(SSA) and La(SSB) ribonucleoproteins. In almost one-third of patients disease involves various extraglandular sites, whereas approximately 5% of patients may also develop malignant B-cell lymphoma. In addition, features of SS are frequently encountered (5-20%) in patients with several other autoimmune rheumatic diseases, and in several respects these 'secondary' forms may be distinct from SS found alone (primary-SS), as well as from each other. The correct diagnosis and management of SS may require consideration from various specialists. Differential diagnosis includes adverse effects of drugs, sarcoidosis, lipoproteinaemias, age-related atrophy, chronic graft-versus-host disease, lymphomas, amyloidosis and infection by human immunodeficiency virus or hepatitis C virus. Based on the sequential application of the validated European classification criteria for SS, a practical algorithm for diagnosis is presented. Despite progress in the understanding of the broad clinicopathological spectrum of the entity, its treatment remains largely empirical and symptomatic. To date, the decision for systemic therapeutic intervention is primarily based on the severity of extraglandular manifestations.

Entities:  

Mesh:

Year:  2000        PMID: 10882215     DOI: 10.1053/berh.1999.0078

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  22 in total

Review 1.  Therapy of Sjögren's syndrome.

Authors:  N M Moutsopoulos; H M Moutsopoulos
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Activation of epithelial and myoepithelial cells in the salivary glands of patients with Sjögren's syndrome: high expression of intercellular adhesion molecule-1 (ICAM.1) in biopsy specimens and cultured cells.

Authors:  E K Kapsogeorgou; I D Dimitriou; R F Abu-Helu; H M Moutsopoulos; M N Manoussakis
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

3.  Correlations between histopathologic and scintigraphic parameters of salivary glands in patients with Sjögren's syndrome.

Authors:  Tamer Aksoy; Pinar Ozgen Kiratli; Belkis Erbas
Journal:  Clin Rheumatol       Date:  2012-06-26       Impact factor: 2.980

Review 4.  The Proteomics of Saliva in Sjögren's Syndrome.

Authors:  Stergios Katsiougiannis; David T W Wong
Journal:  Rheum Dis Clin North Am       Date:  2016-06-21       Impact factor: 2.670

5.  Defective signalling in salivary glands precedes the autoimmune response in the non-obese diabetic mouse model of sialadenitis.

Authors:  F Rosignoli; V Roca; R Meiss; J Leceta; R P Gomariz; C Pérez Leirós
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

6.  Vasoactive intestinal peptide/vasoactive intestinal peptide receptor relative expression in salivary glands as one endogenous modulator of acinar cell apoptosis in a murine model of Sjögren's syndrome.

Authors:  V Hauk; M Calafat; L Larocca; L Fraccaroli; E Grasso; R Ramhorst; C Pérez Leirós
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

Review 7.  The role of epithelial cells in the pathogenesis of Sjögren's syndrome.

Authors:  Menelaos N Manoussakis; Efstathia K Kapsogeorgou
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

8.  A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome.

Authors:  Hao Guo; Changrim Lee; Mihir Shah; Srikanth R Janga; Maria C Edman; Wannita Klinngam; Sarah F Hamm-Alvarez; J Andrew MacKay
Journal:  J Control Release       Date:  2018-10-23       Impact factor: 9.776

9.  X-linked ectodermal dysplasia receptor (XEDAR) gene silencing prevents caspase-3-mediated apoptosis in Sjögren's syndrome.

Authors:  Margherita Sisto; Loredana Lorusso; Sabrina Lisi
Journal:  Clin Exp Med       Date:  2015-12-11       Impact factor: 3.984

10.  Vasoactive intestinal peptide inhibits TNF-alpha-induced apoptotic events in acinar cells from nonobese diabetic mice submandibular glands.

Authors:  Mario Calafat; Luciana Larocca; Valeria Roca; Vanesa Hauk; Nicolás Pregi; Alcira Nesse; Claudia Pérez Leirós
Journal:  Arthritis Res Ther       Date:  2009-04-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.